LiverTox
LiverTox
批准号:
8930884
负责人:
MATTHEW PERRY
金额:
$9.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-22 至 2015-09-21
关键词:
Acute HepatitisAcute Liver FailureAreaBiliaryCaringChemical StructureChemicalsChronic HepatitisClinicalCollaborationsDataDatabasesDiabetes MellitusDigestive System DisordersDisciplineDoseDrug usageFatty LiverFrequenciesGastroenterologyHepatitis BHepatologyHepatotoxicityIndividualInjury to LiverInstitutesInternal MedicineJournalsKidney DiseasesLaboratoriesLettersLinkLiteratureLiver diseasesMedicalMedical LibrariesMedical ResearchNatureObstructionPackage InsertPatientsPatternPediatric Surgical ProceduresPharmaceutical PreparationsPharmacologyPhysiciansPreparationPubMedPublicationsPublished CommentRecordsRegimenRegistriesReportingResourcesSpecialistTest ResultTextbooksUnited States Food and Drug AdministrationUnited States National Library of MedicineVitaminsabstractingcase historydesigndietary supplementsdrug induced liver diseaseforeign languageimprovedliver injurytext searchingweb site
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Drug induced liver injury is an uncommon but important and challenging form of liver disease. When evaluating a patient with new-onset liver disease, drugs, including prescription medications, over-the-counter preparations, vitamins, dietary supplements and herbals, must always be considered as a possible cause. Indeed, the possibility must be entertained even if another cause may seem obvious, such as hepatitis B or C. The reason for this is that drug induced liver injury can be severe and even fatal, but is usually reversed by discontinuation of the offending agent. To continue a medication in the face of drug induced liver injury can have serious consequences.
Drug induced liver injury is a growing challenge because of the ever increasing number of drugs used in medical care and the increasing number of individuals who take them. Among the thousands of drugs available today, several hundred have been linked to liver injury, but the clinical pattern of liver injury is diverse and can mimic almost any form of liver disease. Drug induced liver injury can present in a pattern that is similar to acute hepatitis, chronic hepatitis, acute liver failure, biliary obstruction, or fatty liver disease. To keep track of which drugs cause liver injury and what pattern is typical of each agent is challenging to even the most dedicated subspecialist in the area. Furthermore, the literature on drug induced liver injury is large and dispersed to publications in many disciplines ¿ pharmacology, internal medicine, hepatology, gastroenterology, pediatrics, and surgery. Publications on drug induced liver disease often appear as short reports or letters to the editor that are difficult to access, including many that appear in foreign language journals that may not be available in local medical libraries. As a result, it is difficult to keep abreast of the literature and literature searches on specific medications are often incomplete. While there are several excellent textbooks on drug induced liver disease, they may be difficult to obtain and are rapidly out of date as new medications are introduced and more literature appears.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ENGAGEMENT, TRAINING, AND CAPACITY-BUILDING FOR NLM
-
批准号:10716783
-
项目类别:
-
资助金额:$110.0万
-
财政年份:2022
-
负责人:MATTHEW PERRY
-
依托单位:--
CAPACITY-BUILDING FOR ADVANCING EQUITY THROUGH INFORMATION
-
批准号:10716782
-
项目类别:
-
资助金额:$350.0万
-
财政年份:2022
-
负责人:MATTHEW PERRY
-
依托单位:--
Support for Biomedical and Clinical Information Services - OPTION YEAR 2
-
批准号:8429222
-
项目类别:
-
资助金额:$189.35万
-
财政年份:2009
-
负责人:MATTHEW PERRY
-
依托单位:
Support for Biomedical and Clinical Information Services - OPTION YEAR 2
-
批准号:8358802
-
项目类别:
-
资助金额:$230.92万
-
财政年份:2009
-
负责人:MATTHEW PERRY
-
依托单位:
海外基金